Cadila Healthcare gains on USFDA nod for anti-diabetic drug
The company has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP01-03-2016
01-03-2016
Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated March 01, 2016 titled "Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP".01-03-2016
Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated February 19, 2016 titled "Zydus to commence supplies to the US market from its formulation manufacturing facility at SEZ".19-02-2016
Subdued growth outlook for Cadila
After FDA warning letter for its Moraiya unit, new product approvals after site transfers might take 2-3 quarters08-02-2016
Cadila Q3 net up 38% at Rs 390 cr
The company had posted a net profit of Rs 282 in the same period of previous financial year.05-02-2016
Results Press Release
Cadila Healthcare Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2015.05-02-2016
Announces Q3 Results (Standalone & Consolidated), Limited Review Report (Standalone) for the Quarter ended December 31, 2015
Cadila Healthcare Ltd has announced the following results for the quarter ended December 31, 2015 :The Un-Audited Standalone results for the Quarter ended December 31, 2015The Company has posted a net profit of Rs. 4695 million for the quarter ended December 31, 2015 as compared to Rs. 3612 million for the quarter ended December 31, 2014. Total Income has increased from Rs. 14751 million for the quarter ended December 31, 2014 to...05-02-2016
Shareholding for the Period Ended December 31, 2015
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here23-01-2016
Q3 results on Feb 05, 2016
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 05, 2016, inter alia, to consider & approve the un-audited financial results for the quarter/ nine months ended December 31, 2015 (Q3).Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window shall remain closed...20-01-2016
Cadila gets nod for Rs 5,000-cr QIP
FIPB has approved a total investment proposal of Rs 6,050 cr, with the largest chunk coming from Cadila Healthcare and Nitin Lifesciences14-01-2016